Skip to main content
SpringerLink
Log in

Antiresorptiva in der Behandlung von Knochenmetastasen

  • Chapter
  • First Online:
Knochenmetastasen

  • 1914 Accesses

Zusammenfassung

Prävention und Therapie von Knochenmetastasen werden immer bedeutsamer in der interdisziplinären Versorgung von Patientinnen und Patienten mit malignen Erkrankungen. Bei manifesten Knochenmetastasen ist die Therapie mit hochdosierten Antiresorptiva, Bisphosphonaten und Denosumab als Standard etabliert. Mit dieser Behandlung wird eine Verbesserung der Lebensqualität, eine Verzögerung und Reduktion von Metastasierung und skelettalen Komplikationen, bei manchen Tumor-Entitäten auch ein verbessertes Überleben, erreicht. Die Antitumorwirkung der verwendeten Substanzen ist teilweise in vitro gezeigt; inwiefern sie klinische Relevanz besitzt, müssen entsprechende Studien zeigen. In diesem Kapitel wird die Wirkungsweise antiresorptiver Medikamente beschrieben und ihre Wirkung auf Knochenzellen und den Knochenstoffwechsel erläutert. Ein möglicher Einfluss auf Tumorzellen wird pathophysiologisch dargestellt und diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • AzimH, Azim HA Jr (2013) Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther 13: 195–201

    Article  Google Scholar 

  • Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938

    Article  CAS  PubMed  Google Scholar 

  • Brown-Glaberman U, Stopeck AT (2012) Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 6: 89–99

    CAS  PubMed Central  PubMed  Google Scholar 

  • Carter JA, Ji X, Botteman MF (2013) Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res 13(4): 483–496

    Article  PubMed  Google Scholar 

  • Casimiro S, Mohammad KS, Pires R et al (2013) RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PloS one 8: e63153

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Clezardin P (2011) Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71–79

    Article  CAS  PubMed  Google Scholar 

  • Clezardin P (2012) Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 12: 102–113

    Article  CAS  PubMed  Google Scholar 

  • Clezardin P, Massaia M (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16: 3007–2014

    Article  CAS  PubMed  Google Scholar 

  • Clezardin P, Benzaid I, Croucher PI (2011) Bisphosphonates in preclinical bone oncology. Bone 49: 66–70

    Article  CAS  PubMed  Google Scholar 

  • Coleman R (2011) The use of bisphosphonates in cancer treatment. Ann NY Acad Sci 1218: 3–14

    Article  CAS  PubMed  Google Scholar 

  • Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49: 71–76

    Article  CAS  PubMed  Google Scholar 

  • Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104: 1059–1067

    Article  CAS  PubMed  Google Scholar 

  • Colon-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Mineral Res 25: 91–97

    Article  CAS  Google Scholar 

  • Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49: 42–49

    Article  CAS  PubMed  Google Scholar 

  • Ebert R, Zeck S, Meissner-Weigl J et al (2012) Kruppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone 50: 723–732

    Article  CAS  PubMed  Google Scholar 

  • Ebetino FH, Hogan AM, Sun S et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49: 20–33

    Article  CAS  PubMed  Google Scholar 

  • Fields SZ, Parshad S, Anne M et al (2013) Activin receptor antagonists for cancer-related anemia and bone disease. Exp Opin Invest Drugs 22: 87–101

    Article  CAS  Google Scholar 

  • Gertz BJ, Holland SD, Kline WF et al (1993) Clinical pharmacology of alendronate sodium. Osteoporosis Int 3(Suppl 3): S13–16

    Article  Google Scholar 

  • Gnant M (2012) Adjuvant bisphosphonates: a new standard of care? Curr Opin Oncol 24: 635–642

    Article  CAS  PubMed  Google Scholar 

  • Gnant M, Dubsky P, Hadji P (2012) Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 192: 65–91

    Article  CAS  PubMed  Google Scholar 

  • Goessl C, Katz L, Dougall WC et al (2012) The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann NY Acad Sci 1263: 29–40

    Article  PubMed  Google Scholar 

  • Gonzalez-Suarez E, Jacob AP, Jones J et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468: 103–107

    Article  CAS  PubMed  Google Scholar 

  • Hadji P, Aapro M, Costa L, Gnant M (2012a) Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treatment Rev 38: 815–824

    Article  CAS  Google Scholar 

  • Hadji P, Coleman R, Gnant M, Green J (2012b) The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 23: 2782–2790

    Article  CAS  Google Scholar 

  • Hageman K, Patel KC, Mace K, Cooper MR (2013) The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 47: 1069–1074

    Article  PubMed  Google Scholar 

  • Jakob F, Seefried L, Ebert R (2012) Pathophysiologie des Knochenstoffwechsels bei Osteonekrosen im Zusammenhang mit starker antiresorptiver Therapie. Osteologe 21: 186–192

    Google Scholar 

  • Khosla S, Bilezikian JP, Dempster DW et al (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metabol 97: 2272–2282

    Article  CAS  Google Scholar 

  • Kumagai Y, Hasunuma T, Padhi D (2011) A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone 49: 1101–1107

    Article  CAS  PubMed  Google Scholar 

  • Lacey DL, Boyle WJ, Simonet WS et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discovery 11: 401–419

    Article  CAS  Google Scholar 

  • Langdahl B, Binkley N, Bone H et al (2012) Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Mineral Res 27: 2251–2258

    Article  CAS  Google Scholar 

  • Lawson MA, Xia Z, Barnett BL et al (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mat Res Part B, Applied Biomaterials 92: 149–155

    CAS  PubMed  Google Scholar 

  • Longo V, Brunetti O, D’Oronzo S et al (2012) Therapeutic approaches to myeloma bone disease: an evolving story. Cancer Treat Rev 38: 787–797

    Article  CAS  PubMed  Google Scholar 

  • Martin PL, Bugelski PJ (2012) Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol 166: 806–822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mhaskar R, Redzepovic J, Wheatley K et al (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 5: CD003188

    Google Scholar 

  • Owen S, Ye L, Sanders AJ et al (2013) Expression profile of receptor activator of nuclear-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res 33: 199–206

    CAS  PubMed  Google Scholar 

  • Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME (2013) Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39: 97–104

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Qi WX, Lin F, He AN et al (2013) Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29: 1067–1073

    Article  CAS  PubMed  Google Scholar 

  • Rachner TD, Singh SK, Schoppet M et al (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287: 109–116

    Article  CAS  PubMed  Google Scholar 

  • Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377: 1276–1287

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rachner TD, Hadji P, Hofbauer LC (2012) Novel therapies in benign and malignant bone diseases. Pharmacol Ther 134: 338–344

    Article  CAS  PubMed  Google Scholar 

  • Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Translat Med 9: 177

    Article  CAS  Google Scholar 

  • Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49: 34–41

    Article  CAS  PubMed  Google Scholar 

  • Roodman GD (2012) Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev 31: 569–578

    Article  CAS  PubMed  Google Scholar 

  • Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49: 2–19

    Article  CAS  PubMed  Google Scholar 

  • Santini D, Perrone G, Roato I et al (2011a) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cellular Physiol 226: 780–784

    Article  CAS  Google Scholar 

  • Santini D, Schiavon G, Vincenzi B et al (2011b) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PloS one 6: e19234

    Google Scholar 

  • Schramek D, Leibbrandt A, Sigl V et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98–102

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sharma A, Chatterjee S, Arbab-Zadeh A et al (2013) Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest 144(4): 1311–1322

    Article  CAS  PubMed  Google Scholar 

  • Sottnik JL, Keller ET (2013) Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med 13: 626–639

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Valachis A, Polyzos NP, Coleman RE et al (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18: 353–361

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Wang H, Sarikonda G, Puan KJ et al (2011) Indirect stimulation of human Vgamma2Vdelta2 T cells through alterations in isoprenoid metabolism. J Immunol 187: 5099–5113

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yan T, Yin W, Zhou Q et al (2012) The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 48: 187–195

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Brettreichstr. 11, 97074, Würzburg, Deutschland

    Franz Jakob & Regina Ebert

Authors
  1. Franz Jakob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Regina Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz Jakob .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jakob, F., Ebert, R. (2014). Antiresorptiva in der Behandlung von Knochenmetastasen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation